Ungedeckte medizinische Bedürfnisse sind die Basis unserer Forschung
Further Publications
Related content
COVID-19
Pandémie de COVID-19 : un défi et une chance pour la santé mentale de la population
healthbook TIMES
RECOMMENDED
COVID-19
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, Fagbamigbe AF, Vasileiou E, Grange Z, Shi T, Kerr S, Moore E, Murray JLK, Shah SA, Ritchie L, O'Reilly D, Stock SJ, Beggs J, Chuter A, Torabi F, Akbari A, Bedston S, McMenamin J, Wood R, Tang RSM, de Lusignan S, Hobbs FDR, Woolhouse M, Simpson CR, Robertson C, Sheikh A
doi: 10.1016/S2213-2600(21)00380-5
Infectiology
Infection au VIH : un aperçu de la gestion thérapeutique
healthbook TIMES
RECOMMENDED
COVID-19
Severe COVID-19 among patients with asthma and COPD: a report from the Swedish National Airway Register
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis
Karlsson Sundbaum J, Vanfleteren LEGW, Konradsen JR, Nyberg F, Ekberg-Jansson A, Stridsman C
doi: 10.1177/17534666211049738
Diabetes + Endocrinology
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Lancet
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á
doi: 10.1016/S0140-6736(21)01443-4
COVID-19
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Lancet
RECOVERY Collaborative Group.
doi: 10.1016/S0140-6736(22)01109-6